Zhou Y, Wen J, Wang G. Identification of cytochrome P450 isoenzymes involved in the metabolism of 23-hydroxybetulinic acid in human liver microsomes. Pharm Biol. 2020;58:60-63 pubmed publisher

Liang C, Li J, Lu C, Xie D, Liu J, Zhong C, et al. HIF1α inhibition facilitates Leflunomide-AHR-CRP signaling to attenuate bone erosion in CRP-aberrant rheumatoid arthritis. Nat Commun. 2019;10:4579 pubmed publisher

Wang L, Ma X, Wang J, Li C. In vitro Inhibitory Effects of Cynaroside on Human Liver Cytochrome P450 Enzymes. Pharmacology. 2019;104:296-302 pubmed publisher

Qi X, Dou T, Wang Z, Wu J, Yang L, Zeng S, et al. Inhibition of human cytochrome P450 2A6 by 7-hydroxycoumarin analogues: Analysis of the structure-activity relationship and isoform selectivity. Eur J Pharm Sci. 2019;136:104944 pubmed publisher

Mescher M, Tigges J, Rolfes K, Shen A, Yee J, Vogeley C, et al. The Toll-like receptor agonist imiquimod is metabolized by aryl hydrocarbon receptor-regulated cytochrome P450 enzymes in human keratinocytes and mouse liver. Arch Toxicol. 2019;: pubmed publisher

Luethi D, Hoener M, Krahenbuhl S, Liechti M, Duthaler U. Cytochrome P450 enzymes contribute to the metabolism of LSD to nor-LSD and 2-oxo-3-hydroxy-LSD: Implications for clinical LSD use. Biochem Pharmacol. 2019;164:129-138 pubmed publisher

Fantoukh O, Dale O, Parveen A, Hawwal M, Ali Z, Manda V, et al. Safety Assessment of Phytochemicals Derived from the Globalized South African Rooibos Tea ( Aspalathus linearis) through Interaction with CYP, PXR, and P-gp. J Agric Food Chem. 2019;67:4967-4975 pubmed publisher

Sonawane V, Siddique M, Gatchie L, Williams I, Bharate S, Jayaprakash V, et al. CYP enzymes, expressed within live human suspension cells, are superior to widely-used microsomal enzymes in identifying potent CYP1A1/CYP1B1 inhibitors: Identification of quinazolinones as CYP1A1/CYP1B1 inhibitors that efficiently reverse B[a]P toxi. Eur J Pharm Sci. 2019;131:177-194 pubmed publisher

Kim H, Lee H, Ji H, Lee T, Liu K. Screening of ten cytochrome P450 enzyme activities with 12 probe substrates in human liver microsomes using cocktail incubation and liquid chromatography-tandem mass spectrometry. Biopharm Drug Dispos. 2019;40:101-111 pubmed publisher

Nishihara M, Yamasaki H, Czerniak R, Jenkins H. In Vitro Assessment of Potential for CYP-Inhibition-Based Drug-Drug Interaction Between Vonoprazan and Clopidogrel. Eur J Drug Metab Pharmacokinet. 2019;44:217-227 pubmed publisher

Zhang J, Li C, Zhang J, Zhang F. In vitro inhibitory effects of sophocarpine on human liver cytochrome P450 enzymes. Xenobiotica. 2019;49:1127-1132 pubmed publisher

Parmentier Y, Pothier C, Hewitt N, Vincent L, Caradec F, Liu J, et al. Direct and quantitative evaluation of the major human CYP contribution (fmCYP) to drug clearance using the in vitro Silensomes™ model. Xenobiotica. 2019;49:22-35 pubmed publisher

Liederer B, Cheong J, Chou K, Dragovich P, Le H, Liang X, et al. Preclinical Assessment of the ADME, Efficacy and Drug-Drug Interaction Potential of a Novel NAMPT Inhibitor. Xenobiotica. 2018;:1-56 pubmed publisher

Wei J, Zhang H, Zhao Q. In vitro inhibitory effects of Friedelin on human liver cytochrome P450 enzymes. Pharm Biol. 2018;56:363-367 pubmed publisher

Ramanathan R, Ghosal A, Ramanathan L, Comstock K, Shen H, Ramanathan D. HPLC-high-resolution mass spectrometry with polarity switching for increasing throughput of human in vitro cocktail drug-drug interaction assay. Bioanalysis. 2018;10:659-671 pubmed publisher

Sawant Basak A, Obach R, Doran A, Lockwood P, Schildknegt K, Gao H, et al. Metabolism of a 5HT6 Antagonist, 2-Methyl-1-(Phenylsulfonyl)-4-(Piperazin-1-yl)-1H-Benzo[d]imidazole (SAM-760): Impact of Sulfonamide Metabolism on Diminution of a Ketoconazole-Mediated Clinical Drug-Drug Interaction. Drug Metab Dispos. 2018;46:934-942 pubmed publisher

Choi Y, Lee J, Ryu C, Chi Y, Paik S, Kim S. Role of cytochrome P450 enzymes in fimasartan metabolism in vitro. Food Chem Toxicol. 2018;115:375-384 pubmed publisher

Iwaki M, Niwa T, Nakamura Y, Kawase A, Komura H. Relative contribution of rat CYP isoforms responsible for stereoselective metabolism of carvedilol. J Toxicol Sci. 2018;43:59-63 pubmed publisher

Ekow Thomford N, Dzobo K, Adu F, Chirikure S, Wonkam A, Dandara C. Bush mint (Hyptis suaveolens) and spreading hogweed (Boerhavia diffusa) medicinal plant extracts differentially affect activities of CYP1A2, CYP2D6 and CYP3A4 enzymes. J Ethnopharmacol. 2018;211:58-69 pubmed publisher

Sohlenius Sternbeck A, Meyerson G, Hagbjörk A, Juric S, Terelius Y. A strategy for early-risk predictions of clinical drug-drug interactions involving the GastroPlusTM DDI module for time-dependent CYP inhibitors. Xenobiotica. 2018;48:348-356 pubmed publisher

Hao X, Yuan J, Xu Y, Wang Z, Hou J, Hu T. In vitro inhibitory effects of pristimerin on human liver cytochrome P450 enzymes. Xenobiotica. 2018;48:1185-1191 pubmed publisher

Einolf H, Lin W, Won C, Wang L, Gu H, Chun D, et al. Physiologically Based Pharmacokinetic Model Predictions of Panobinostat (LBH589) as a Victim and Perpetrator of Drug-Drug Interactions. Drug Metab Dispos. 2017;45:1304-1316 pubmed publisher

Wu X, Zhang Q, Guo J, Jia Y, Zhang Z, Zhao M, et al. Metabolism of F18, a Derivative of Calanolide A, in Human Liver Microsomes and Cytosol. Front Pharmacol. 2017;8:479 pubmed publisher

Feng Y, Wang C, Tian X, Huo X, Feng L, Sun C, et al. In vitro phase I metabolism of gamabufotalin and arenobufagin: Reveal the effect of substituent group on metabolic stability. Fitoterapia. 2017;121:38-45 pubmed publisher

Zhong Q, Shi Z, Zhang L, Zhong R, Xia Z, Wang J, et al. The potential of Epimedium koreanum Nakai for herb-drug interaction. J Pharm Pharmacol. 2017;69:1398-1408 pubmed publisher

Siebert M, Mattos J, Toledo Silva G, Razzera G, Bainy A. Candidate cytochrome P450 genes for ethoxyresorufin O-deethylase activity in oyster Crassostrea gigas. Aquat Toxicol. 2017;189:142-149 pubmed publisher

Liu L, Sun S, Rui H, Li X. In vitro inhibitory effects of dihydromyricetin on human liver cytochrome P450 enzymes. Pharm Biol. 2017;55:1868-1874 pubmed publisher

Ollikainen E, Liu D, Kallio A, Mäkilä E, Zhang H, Salonen J, et al. The impact of porous silicon nanoparticles on human cytochrome P450 metabolism in human liver microsomes in vitro. Eur J Pharm Sci. 2017;104:124-132 pubmed publisher

Yu J, Choi M, Park J, Rehman S, Nakamura K, Yoo H. Inhibitory Effects of Garcinia cambogia Extract on CYP2B6 Enzyme Activity. Planta Med. 2017;83:895-900 pubmed publisher

Einolf H, Zhou J, Won C, Wang L, Rebello S. A Physiologically-Based Pharmacokinetic Modeling Approach To Predict Drug-Drug Interactions of Sonidegib (LDE225) with Perpetrators of CYP3A in Cancer Patients. Drug Metab Dispos. 2017;45:361-374 pubmed publisher

Gillen M, Yang C, Wilson D, Valdez S, Lee C, Kerr B, et al. Evaluation of Pharmacokinetic Interactions Between Lesinurad, a New Selective Urate Reabsorption Inhibitor, and CYP Enzyme Substrates Sildenafil, Amlodipine, Tolbutamide, and Repaglinide. Clin Pharmacol Drug Dev. 2017;6:363-376 pubmed publisher

Sekiguchi N, Nagao S, Takanashi K, Kato M, Kaneko A, Morita K, et al. Preclinical evaluation of the potential for cytochrome P450 inhibition and induction of the selective ALK inhibitor, alectinib. Xenobiotica. 2017;47:1042-1051 pubmed publisher

Iwaki M, Niwa T, Bandoh S, Itoh M, Hirose H, Kawase A, et al. Application of substrate depletion assay to evaluation of CYP isoforms responsible for stereoselective metabolism of carvedilol. Drug Metab Pharmacokinet. 2016;31:425-432 pubmed publisher

Siebert M, Mattos J, Piazza C, de Lima D, Gomes C, de Melo C, et al. Characterization of ethoxyresorufin O-deethylase activity (EROD) in oyster Crassostrea brasiliana. Comp Biochem Physiol B Biochem Mol Biol. 2017;203:115-121 pubmed publisher

Feng R, Tan X, Wen B, Shou J, Fu J, He C, et al. Interaction effects on cytochrome P450 both in vitro and in vivo studies by two major bioactive xanthones from Halenia elliptica D. Don. Biomed Chromatogr. 2016;30:1953-1962 pubmed publisher

Zhang H, Ya G, Rui H. Inhibitory Effects of Triptolide on Human Liver Cytochrome P450 Enzymes and P-Glycoprotein. Eur J Drug Metab Pharmacokinet. 2017;42:89-98 pubmed publisher

Okubo M, Narita M, Murayama N, Akimoto Y, Goto A, Yamazaki H. Individual differences in in vitro and in vivo metabolic clearances of the antipsychotic drug olanzapine from non-smoking and smoking Japanese subjects genotyped for cytochrome P4502D6 and flavincontaining monooxygenase 3. Hum Psychopharmacol. 2016;31:83-92 pubmed publisher

Qin C, Ren X, Zhou H, Mao X, Liu Z. Inhibitory effect of salvianolate on human cytochrome P450 3A4 in vitro involving a noncompetitive manner. Int J Clin Exp Med. 2015;8:15549-55 pubmed

Haarhoff Z, Wagner A, Picard P, Drexler D, Zvyaga T, Shou W. Coupling Laser Diode Thermal Desorption with Acoustic Sample Deposition to Improve Throughput of Mass Spectrometry-Based Screening. J Biomol Screen. 2016;21:165-75 pubmed publisher

Shi X, Yang S, Zhang G, Song Y, Su D, Liu Y, et al. The different metabolism of morusin in various species and its potent inhibition against UDP-glucuronosyltransferase (UGT) and cytochrome p450 (CYP450) enzymes. Xenobiotica. 2016;46:467-76 pubmed publisher

Wu J, Ge G, He Y, Wang P, Dai Z, Ning J, et al. Gomisin A is a Novel Isoform-Specific Probe for the Selective Sensing of Human Cytochrome P450 3A4 in Liver Microsomes and Living Cells. AAPS J. 2016;18:134-45 pubmed publisher

Thelingwani R, Leandersson C, Bonn B, Smith P, Chibale K, Masimirembwa C. Characterisation of artemisinin-chloroquinoline hybrids for potential metabolic liabilities. Xenobiotica. 2016;46:234-40 pubmed publisher

Seah T, Tay Y, Tan H, Muhammad T, Wahab H, Tan M. Determination of CYP3A4 Inducing Properties of Compounds Using a Laboratory-Developed Cell-Based Assay. Int J Toxicol. 2015;34:454-68 pubmed publisher

Feng R, Shou J, Zhao Z, He C, Ma C, Huang M, et al. Transforming berberine into its intestine-absorbable form by the gut microbiota. Sci Rep. 2015;5:12155 pubmed publisher

Pang C, Sheng Y, Jiang P, Wei H, Ji L. Chlorogenic acid prevents acetaminophen-induced liver injury: the involvement of CYP450 metabolic enzymes and some antioxidant signals. J Zhejiang Univ Sci B. 2015;16:602-10 pubmed publisher

Gong J, Eley T, He B, Arora V, Philip T, Jiang H, et al. Characterization of ADME properties of [(14)C]asunaprevir (BMS-650032) in humans. Xenobiotica. 2016;46:52-64 pubmed publisher

Sasahara K, Shimokawa Y, Hirao Y, Koyama N, Kitano K, Shibata M, et al. Pharmacokinetics and Metabolism of Delamanid, a Novel Anti-Tuberculosis Drug, in Animals and Humans: Importance of Albumin Metabolism In Vivo. Drug Metab Dispos. 2015;43:1267-76 pubmed publisher

Peng Y, Wu H, Zhang X, Zhang F, Qi H, Zhong Y, et al. A comprehensive assay for nine major cytochrome P450 enzymes activities with 16 probe reactions on human liver microsomes by a single LC/MS/MS run to support reliable in vitro inhibitory drug-drug interaction evaluation. Xenobiotica. 2015;45:961-77 pubmed publisher

Mosure K, Knipe J, Browning M, Arora V, Shu Y, Phillip T, et al. Preclinical Pharmacokinetics and In Vitro Metabolism of Asunaprevir (BMS-650032), a Potent Hepatitis C Virus NS3 Protease Inhibitor. J Pharm Sci. 2015;104:2813-23 pubmed publisher

Kazmi F, Barbara J, Yerino P, Parkinson A. A long-standing mystery solved: the formation of 3-hydroxydesloratadine is catalyzed by CYP2C8 but prior glucuronidation of desloratadine by UDP-glucuronosyltransferase 2B10 is an obligatory requirement. Drug Metab Dispos. 2015;43:523-33 pubmed publisher

Ning J, Yu Z, Hu L, Wang C, Huo X, Deng S, et al. Characterization of phase I metabolism of resibufogenin and evaluation of the metabolic effects on its antitumor activity and toxicity. Drug Metab Dispos. 2015;43:299-308 pubmed publisher

Shinde D, Kim M, Jeong E, Kim Y, Lee J, Shin J, et al. Enantioselective N-demethylation and hydroxylation of sibutramine in human liver microsomes and recombinant cytochrome p-450 isoforms. J Toxicol Environ Health A. 2014;77:1419-30 pubmed publisher

Wu J, Shaw J, Dubaisi S, Valeriote F, Li J. In vitro metabolism and drug-drug interaction potential of UTL-5g, a novel chemo- and radioprotective agent. Drug Metab Dispos. 2014;42:2058-67 pubmed publisher

Thelingwani R, Bonn B, Chibale K, Masimirembwa C. Physicochemical and drug metabolism characterization of a series of 4-aminoquinoline-3-hydroxypyridin-4-one hybrid molecules with antimalarial activity. Expert Opin Drug Metab Toxicol. 2014;10:1313-24 pubmed publisher

Lee S, Jang H, Lee J, Ma J, Oh S, Kim S. Inhibitory effects of Hwang-Ryun-Hae-Dok-Tang on cytochrome P450 in human liver microsomes. Xenobiotica. 2015;45:131-8 pubmed publisher

Nirogi R, Palacharla R, Uthukam V, Manoharan A, Srikakolapu S, Kalaikadhiban I, et al. Chemical inhibitors of CYP450 enzymes in liver microsomes: combining selectivity and unbound fractions to guide selection of appropriate concentration in phenotyping assays. Xenobiotica. 2015;45:95-106 pubmed publisher

Barnes K, Rowland A, Polasek T, Miners J. Inhibition of human drug-metabolising cytochrome P450 and UDP-glucuronosyltransferase enzyme activities in vitro by uremic toxins. Eur J Clin Pharmacol. 2014;70:1097-106 pubmed publisher

Zhu L, Liu X, Zhu L, Zhang X, Fu X, Huang J, et al. Identification of human cytochrome P450 isozymes involved in the metabolism of naftopidil enantiomers in vitro. J Pharm Pharmacol. 2014;66:1534-51 pubmed publisher

Lee S, Jang H, Lee J, Kwon K, Oh S, Kim S. Inhibition of cytochrome P450 by ethambutol in human liver microsomes. Toxicol Lett. 2014;229:33-40 pubmed publisher

Wojcikowski J, Basińska A, Daniel W. The cytochrome P450-catalyzed metabolism of levomepromazine: a phenothiazine neuroleptic with a wide spectrum of clinical application. Biochem Pharmacol. 2014;90:188-95 pubmed publisher

Li L, Tu M, Yang X, Sun S, Wu X, Zhou H, et al. The contribution of human OCT1, OCT3, and CYP3A4 to nitidine chloride-induced hepatocellular toxicity. Drug Metab Dispos. 2014;42:1227-34 pubmed publisher

Lawrence S, Nguyen D, Bowen C, Richards Peterson L, Skordos K. The metabolic drug-drug interaction profile of Dabrafenib: in vitro investigations and quantitative extrapolation of the P450-mediated DDI risk. Drug Metab Dispos. 2014;42:1180-90 pubmed publisher

Ericsson T, Sundell J, Torkelsson A, Hoffmann K, Ashton M. Effects of artemisinin antimalarials on Cytochrome P450 enzymes in vitro using recombinant enzymes and human liver microsomes: potential implications for combination therapies. Xenobiotica. 2014;44:615-26 pubmed publisher

Yoda N, Emoto C, Date S, Kondo S, Miyake M, Nakazato S, et al. Characterization of intestinal and hepatic P450 enzymes in cynomolgus monkeys with typical substrates and inhibitors for human P450 enzymes. Xenobiotica. 2012;42:719-30 pubmed publisher

Chu C, Pan K, Yao H, Hsu J. Development of a whole-cell screening system for evaluation of the human CYP1A2-mediated metabolism. Biotechnol Bioeng. 2011;108:2932-40 pubmed publisher

Wu G, Vashishtha S, Erve J. Characterization of glutathione conjugates of duloxetine by mass spectrometry and evaluation of in silico approaches to rationalize the site of conjugation for thiophene containing drugs. Chem Res Toxicol. 2010;23:1393-404 pubmed publisher

Kot M, Daniel W. Effect of diethyldithiocarbamate (DDC) and ticlopidine on CYP1A2 activity and caffeine metabolism: an in vitro comparative study with human cDNA-expressed CYP1A2 and liver microsomes. Pharmacol Rep. 2009;61:1216-20 pubmed

Kazui M, Nishiya Y, Ishizuka T, Hagihara K, Farid N, Okazaki O, et al. Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite. Drug Metab Dispos. 2010;38:92-9 pubmed publisher

He Y, Yang L, Liu Y, Zhang J, Tang J, Su J, et al. Characterization of cardamonin metabolism by P450 in different species via HPLC-ESI-ion trap and UPLC-ESI-quadrupole mass spectrometry. Acta Pharmacol Sin. 2009;30:1462-70 pubmed publisher

Lacour S, Antonios D, Gautier J, Pallardy M. Acetaminophen and lipopolysaccharide act in synergy for the production of pro-inflammatory cytokines in murine RAW264.7 macrophages. J Immunotoxicol. 2009;6:84-93 pubmed publisher

Lakshmi V, Hsu F, Zenser T. Identification of new 2-amino-3-methylimidazo[4,5-f]quinoline urinary metabolites from beta-naphthoflavone-treated mice. Drug Metab Dispos. 2009;37:1690-7 pubmed publisher

Ishida K, Taguchi M, Akao T, Hashimoto Y. Involvement of the CYP1A subfamily in stereoselective metabolism of carvedilol in beta-naphthoflavone-treated Caco-2 cells. Biol Pharm Bull. 2009;32:513-6 pubmed

Fairman D, Collins C, Chapple S. Progress curve analysis of CYP1A2 inhibition: a more informative approach to the assessment of mechanism-based inactivation?. Drug Metab Dispos. 2007;35:2159-65 pubmed

Polasek T, Miners J. In vitro approaches to investigate mechanism-based inactivation of CYP enzymes. Expert Opin Drug Metab Toxicol. 2007;3:321-9 pubmed

Guo J, Nikolic D, Chadwick L, Pauli G, van Breemen R. Identification of human hepatic cytochrome P450 enzymes involved in the metabolism of 8-prenylnaringenin and isoxanthohumol from hops (Humulus lupulus L.). Drug Metab Dispos. 2006;34:1152-9 pubmed

Fuhr U, Kober S, Zaigler M, Mutschler E, Spahn Langguth H. Rate-limiting biotransformation of triamterene is mediated by CYP1A2. Int J Clin Pharmacol Ther. 2005;43:327-34 pubmed

Winchell G, Mistry G, Kari P, Marbury T, Miller J, Simpson R, et al. The effect of ketoconazole on the pharmacokinetics of a selective alpha 1A-adrenoceptor antagonist. J Clin Pharmacol. 2005;45:699-703 pubmed

Nagashima A, Tanaka E, Inomata S, Honda K, Misawa S. A study of the in vitro interaction between lidocaine and premedications using human liver microsomes. J Clin Pharm Ther. 2005;30:185-8 pubmed

Peng W, Li H, Zhou H. [Mechanism of mono-hydroxylation of daidzein in human liver microsomes]. Yao Xue Xue Bao. 2004;39:892-6 pubmed

Di Marco A, Marcucci I, Chaudhary A, Taliani M, Laufer R. Development and validation of a high-throughput radiometric cyp2c9 inhibition assay using tritiated diclofenac. Drug Metab Dispos. 2005;33:359-64 pubmed

Shertzer H, Clay C, Genter M, Schneider S, Nebert D, Dalton T. Cyp1a2 protects against reactive oxygen production in mouse liver microsomes. Free Radic Biol Med. 2004;36:605-17 pubmed

Khojasteh Bakht S, Rossulek M, Fouda H, Prakash C. Identification of the human cytochrome P450s responsible for the in vitro metabolism of a leukotriene B4 receptor antagonist, CP-195,543. Xenobiotica. 2003;33:1201-10 pubmed

Kobayashi K, Urashima K, Shimada N, Chiba K. Selectivities of human cytochrome P450 inhibitors toward rat P450 isoforms: study with cDNA-expressed systems of the rat. Drug Metab Dispos. 2003;31:833-6 pubmed

Hyland R, Jones B, Smith D. Identification of the cytochrome P450 enzymes involved in the N-oxidation of voriconazole. Drug Metab Dispos. 2003;31:540-7 pubmed

Labbe L, Abolfathi Z, Lessard E, Pakdel H, Beaune P, Turgeon J. Role of specific cytochrome P450 enzymes in the N-oxidation of the antiarrhythmic agent mexiletine. Xenobiotica. 2003;33:13-25 pubmed

Avery M, Meek C, Audus K. The presence of inducible cytochrome P450 types 1A1 and 1A2 in the BeWo cell line. Placenta. 2003;24:45-52 pubmed

Turesky R, Guengerich F, Guillouzo A, Langouet S. Metabolism of heterocyclic aromatic amines by human hepatocytes and cytochrome P4501A2. Mutat Res. 2002;506-507:187-95 pubmed

Brachtendorf L, Jetter A, Beckurts K, Holscher A, Fuhr U. Cytochrome P450 enzymes contributing to demethylation of maprotiline in man. Pharmacol Toxicol. 2002;90:144-9 pubmed

Segura J, Garcia I, Tarrus E. Some pharmacokinetic characteristics of furafylline, a new 1,3,8-trisubstituted xanthine. J Pharm Pharmacol. 1986;38:615-8 pubmed

Sesardic D, Boobis A, Murray B, Murray S, Segura J, de la Torre R, et al. Furafylline is a potent and selective inhibitor of cytochrome P450IA2 in man. Br J Clin Pharmacol. 1990;29:651-63 pubmed

Boulenc X, Bourrie M, Fabre I, Roque C, Joyeux H, Berger Y, et al. Regulation of cytochrome P450IA1 gene expression in a human intestinal cell line, Caco-2. J Pharmacol Exp Ther. 1992;263:1471-8 pubmed